KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial.

Yehyun Park, Jun Kyu Lee, Kwang Hyuck Lee, Taejun Kim, Sun Hyung Kang, Dong-Won Ahn, Sung Bum Kim, Seong-Jung Kim

United European Gastroenterol J 14(1) e70147

PMID41284133
PMCIDPMC12811999
DOI10.1002/ueg2.70147
发表日期2025-11-24
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:ROC 图;FIGURE 3:AI 判定为 other。
摘要

摘要

BACKGROUND AND AIMS: Remimazolam, a new ultra-short-acting benzodiazepine, is a safe and effective option for procedural sedation. Nevertheless, to date, no study has directly compared remimazolam and midazolam in diagnostic upper gastrointestinal endoscopy. This study aimed to evaluate the efficacy and safety of remimazolam compared with those of midazolam in this setting. METHODS: This multicenter, single-blind, randomized, positive-control, superiority, investigator-initiated phase III trial enrolled patients who were scheduled to undergo diagnostic upper gastrointestinal endoscopy at seven academic teaching hospitals from April 2023 to January 2024. Participants were randomly assigned to receive remimazolam or midazolam (1:1 ratio). The primary endpoint was total procedure time, defined as the duration from the first sedative administration to discharge. RESULTS: Of 133 randomized patients, 132 (remimazolam group, n = 66; midazolam group, n = 66) underwent upper endoscopy with sedation. The total procedure time was significantly shorter in the remimazolam group (30.3 vs. 48.5 min, p < 0.001). Sedation-related times (i.e., induction, sedation, recovery, and discharge times) were also significantly shorter in the remimazolam group (all p < 0.001). The incidence of adverse events did not significantly differ between the groups; however, the incidence rates of hypotension, bradycardia, and paradoxical reactions were lower in the remimazolam group. When compared to previous sedation experiences, patient satisfaction was higher in the remimazolam group (p < 0.001). CONCLUSIONS: Compared with midazolam, the use of remimazolam in diagnostic upper gastrointestinal endoscopy allows for faster sedation induction and recovery, more rapid discharge, and higher patient satisfaction compared with previous sedation experiences, while maintaining a safety profile similar to that of midazolam. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05836545).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Overview of the study progress and patient enrollment status.
非 KM Figure
FIGURE 2Comparison of total procedure time between the remimazolam and midazolam groups.
非 KM Figure
FIGURE 3Changes in the modified observer's assessment of alertness and sedation (MOAA/S) scale scores over time after administration of study medications.
非 KM Figure